RxDoctor Payments Data

Jonathan Greenblatt, MD

Cardiovascular Disease · Miami Beach, FLNPI 1912960568

Payments from drug & device makers

$14,214in general payments, 2019–2025

Across 124 payments — averaging $114.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$9K
  • E.r. Squibb & Sons, L.L.C.$3K
  • AstraZeneca$226
  • Abbott$187
  • Johnson & Johnson$157
  • Boston Scientific$156
  • plus $2K from 26 others

What the payments were for

  • Speaking & faculty fees$10,65075%
  • Travel & lodging$5204%
  • Food & beverage$3,03321%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,214 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$151,820
Medicare patients
260
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$32,068
EntrestoSacubitril/Valsartan11$19,247
XareltoRivaroxaban15$12,898
FarxigaDapagliflozin Propanediol13$9,400
Metoprolol Succinate65$671
Rosuvastatin Calcium30$333
Nifedipine ErNifedipine13$332
Atorvastatin Calcium27$324
Amlodipine Besylate49$280
Doxazosin Mesylate12$254
Carvedilol22$168
Levothyroxine Sodium13$127
Losartan Potassium22$122
Lisinopril17$105
Furosemide23$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$32,06830 claims
NovartisEntresto$140$19,24711 claims
Johnson & JohnsonXarelto$157$12,89815 claims
AstraZenecaFarxiga$226$9,40013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →